echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Seven domestic new crown vaccines are being accepted by WHO's emergency use list. Experts call on China's vaccine industry to accelerate the process of internationalization

    Seven domestic new crown vaccines are being accepted by WHO's emergency use list. Experts call on China's vaccine industry to accelerate the process of internationalization

    • Last Update: 2021-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the Global Health Innovation Center of Duke University in the United States released the "New Coronary Pneumonia Vaccine Market Launch and Scale Speedometer (The Launch and Scale Speedometer)".


    While this brings severe challenges to the world vaccine industry, including China, it also allows the world to see infinite opportunities brought about by international cooperation.


    The current global supply of new crown vaccines is obviously insufficient, and the global distribution of new crown vaccines has appeared unequal.


    In response to this inequality, “China's new crown vaccine is being used as a global public product to contribute to the realization of the accessibility and affordability of vaccines in developing countries.


    Feng Duojia, president of the China Vaccine Industry Association, said that up to now, the domestic use of my country's domestic new crown vaccine has exceeded 130 million doses, and the number of exports has exceeded 100 million doses, which are basically the same.


    "China's vaccine has long-term responsibility to provide global public products and services.


    With the help of the World Health Organization's Emergency Use List (WHO EUL) program, China's new crown vaccine has obtained a platform to provide international services.


    On October 8, 2020, China signed an agreement with the Global Alliance for Vaccines and Immunization to formally join the "New Coronary Pneumonia Vaccine Implementation Plan" (COVAX), upholding the concept of a community of human health and fulfilling its own commitments to promote vaccines as global public products.


    "China's vaccine industry is very active and is actively contributing to world public health.


    "China's vaccines are accelerating the historic transformation from a major vaccine country to a powerful vaccine country in terms of quality and production.


    So, how should the Chinese vaccine industry accelerate the process of internationalization and achieve "excellent" and "strong"? In Feng Duojia's view, "excellent" means that the whole process and all elements of vaccine products and services are in line with international standards; "strong" means having a strong vaccine industry capability and production efficiency.


    Dong Jian, CEO of WuXi Hyde and Senior Vice President of WuXi Biologics, also said that ensuring service quality, ensuring production scale and cost control will help Chinese companies enter the international market.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.